Neoadjuvant model in cancer treatment: From clinical opportunity to health-care utility

Daniele Generali*, Stephen B. Fox, Massimo Cristofanilli, Giampaolo Bianchini, Alberto Zambelli, Christos Hatzis, Massimo Barberis, Rosanna Tarricone, Alberto Bottini, Camillo Rossi, Michele Tringali

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

In the last few decades, research has demonstrated that cancer can be treated and cured if diagnosed at very early stage and a proper therapeutic strategy is adopted. Recent omics-based approaches have unveiled the molecular mechanisms of cancer tumorigenesis and have aided in identifying next-generation molecular markers for early diagnosis, prognosis, and targeted therapy. New tests based on genomic profiling, circulating tumor cells, or mutation profiling are appraised for purpose by Health Technology Assessment. The potential clinical utility of these tests lies on their ability to discriminate between patients who will benefit to a greater or lesser extent from a therapeutic intervention. Assessment of new technologies for the management of cancer could be of interest to other countries given the potentially high impact that they can have on the quality and cost of health care services.

Original languageEnglish (US)
Pages (from-to)1-3
Number of pages3
JournalJournal of the National Cancer Institute - Monographs
Volume2015
Issue number51
DOIs
StatePublished - May 1 2015

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Neoadjuvant model in cancer treatment: From clinical opportunity to health-care utility'. Together they form a unique fingerprint.

Cite this